Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is a good question. I bought it in my fidelity ira and didn't concern myself about it since this is a long term hold. That may explain why my purchase price was slightly less than the ask showed at the time. I thought I was hitting the ask at .215 and got filled at .212 after going back and looking at my order. I filled at .212
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
looks very nice keep it up!))
That works. Is that in US or Canadian dollars?
Try SCTPF...
SSS.V http://investorshub.advfn.com/boards/board.aspx?board_id=11538
SCTPF http://investorshub.advfn.com/boards/board.aspx?board_id=16906 on pink sheets, but, the chart in this ibox is SSS.V since stockcharts still doesn't have the chart up for the US ticker.
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
Karin, SSS.V doesn't work for me. Is there another symbol? I know you gave it to me but I think I deleted it. Sorry.
SSS.V chart. If it follows it's normal pattern it should have a slight pull back and keep going since it broke out of the .21 range. ;) The insider buying in December is what got me into this one. Somethings coming. ;)
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
nice board bro thanks and GL to all!))
Stem Cell Battles http://stemcellbattles.wordpress.com/
NEW!!!
Cord Blood America Contracts With Center for Stem Cell Awareness to Sell Collection and Storage Services in Florida
6:00a ET January 19, 2010 (PR NewsWire)
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has contracted with The Center for Stem Cell Awareness to re-sell its stem cell collection and storage services.
The Center for Stem Cell Awareness, Inc., Sarasota, Florida (www.babyslifeline.com) has contracted to sell these services throughout the state of Florida.
"This is another very important step forward for Cord Blood America. As a direct result of processing and storing cord blood stem cells in our own laboratory, it allows CBAI to contract partners who will sell our services without CBAI's out-of-pocket investment to develop a new territory. We are fortunate to work with The Center for Stem Cell Awareness, and are very pleased to make this announcement," said Matthew Schissler, CBAI co-founder and CEO.
The Center for Stem Cell Awareness, founded by Joan and Jeff Williams, was a personal endeavor based on a real life scenario with their daughter. Realizing that most expectant parents have no idea about the research and medical breakthroughs with cord blood stem cells, they started their company with the goal of providing an educational resource for expectant families and their physicians to draw upon.
Celgene Corporation to Announce Fourth Quarter and Full-Year 2009 Results on January 28, 2010
Date : 01/19/2010 @ 7:30AM
Source : Business Wire
Stock : Celgene Corporation (CELG)
Quote : 57.52 0.0 (0.00%) @ 7:22AM
Celgene Corporation to Announce Fourth Quarter and Full-Year 2009 Results on January 28, 2010
Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 28, 2010 at 9 a.m. ET to discuss the company’s fourth quarter and full-year 2009 financial and operational results. The webcast will be available in the investor relations section of the company’s Web site at www.celgene.com
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company’s Web site at www.celgene.com
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control. The Company’s actual results, performance, or achievements could be materially different from those projected by these forward-looking statements. The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company’s filings with the Securities and Exchange Commission, such as the Company’s Form 10-K, 10-Q and 8-K reports. Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements
SSS.V chart...it's made a nice move today! ;) http://investorshub.advfn.com/boards/board.aspx?board_id=11538
And, the same ticker in the US is SCTPF http://investorshub.advfn.com/boards/board.aspx?board_id=16906
If interested, I'd check both boards since you'll have different posters on the two boards. You'll also notice the Canadian ticker has much more volume than the US ticker. Don't worry about that volume discrepancy. No matter which ticker is traded it all ends up on the Canadian exchange. Just watch what is happening on the Canadian exchange. Even though US markets were closed today we had a great move in Canada. ;)
Links of importance for those that trade Canadian stocks:
Sedar
http://www.sedar.com/homepage_en.htm
TMX.
http://www.tmx.com/
TMXmoney
http://www.tmxmoney.com/en/index.html
Canadian Insider
http://canadianinsider.com/coReport/allTransactions.php?ticker=sss
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
New Ways to Treat Multiple Sclerosis By THOMAS GRYTA and JON KAMP
Multiple sclerosis seems to damage the central nervous system at a pace faster than the body's own repair mechanism can keep up. In an attempt to find new approaches to treat the disease, scientists are exploring techniques to give the repair process a boost.
An important area of research focuses on ways to help the body regenerate a fatty substance called myelin, which is damaged by attacks brought on by MS patients' own immune system. Myelin protects nerve fibers, or axons, much like insulation on electrical wire. Currently, the principal treatment for MS is with medications that aim to slow the disease's progression, but don't help repair the damage.
Multiple sclerosis is a chronic, inflammatory condition that can be disabling in advanced stages. The disease affects an estimated 400,000 people in the U.S. While typically not fatal, it can cause an array of debilitating symptoms, including fatigue, vision problems and even paralysis.
Scientists are tantalized by signs the body can create new myelin. Bruce Trapp, head of the neurosciences department at the Cleveland Clinic's Lerner Research Institute, has studied myelin for decades by dissecting brains of deceased MS patients. "We know the MS brain can repair its lesions," or areas of damage, says Dr. Trapp, who founded a small start-up company Renovo Neural Inc., that is trying to grow and activate cells that create myelin.
Myelin-rebuilding research is in the early stages and there is a long road ahead to prove it could work safely in people—it hasn't progressed beyond rodents. Researchers believe it will be important to replace myelin soon after it's damaged, and before harm to nerve fibers has advanced too far.
Research on other MS treatment strategies could yield results first. MS often requires lifelong treatment, and MS drugs brought in more than $8.7 billion in 2009 revenue worldwide, according to Bernstein Research.
Biogen Idec Inc., a Cambridge, Mass., biotechnology company has a big business in MS drugs and is now targeting myelin repair. Biogen biologist Sha Mi discovered a molecule dubbed "Lingo-1" that Biogen believes stops myelin production in adults after axons are well covered. After years of work Biogen researchers found an antibody in 2007 that they believe can safely turn off Lingo-1, and allow myelin regeneration. Biogen plans to launch its first study on humans soon.
Some researchers, though, are wary of any steps that shut off potentially important processes. Likewise, artificially boosting myelin production could trigger unexpected side effects.
While people with MS produce new myelin, the rebuilding effort often doesn't keep pace with the damage, and the efficiency of that process decreases with age even in healthy adults.
In patients with the disease, debris created when myelin falls off can bog down the system, and in the progressive-disease stage many patients enter into a feedback loop of chronic inflammation.
Peter Calabresi, director of the Johns Hopkins Multiple Sclerosis Center in Baltimore, is screening already approved medicines, as well as unsuccessful drugs shelved by developers, to see if they can help the cells that grow myelin—oligodendrocyte progenitor cells—develop more efficiently. Finding that an already approved drug, such as an antidepressant, works would be helpful because the side effects are already understood.
Anna Williams, a neurologist at the University of Edinburgh Multiple Sclerosis Centre in Scotland, has focused on trying to direct oligodendrocytes to damaged areas. She and other researchers are also working to trigger those cells to make myelin, which is another important step.
Another approach to fighting MS in the research stage: stem cells transplant. Steven Goldman, head of the cell and gene therapy division at the University of Rochester Medical Center, used this technique to successfully remyelinate the entire nervous system of mice born with no myelin. Such mice usually live four or five months, but some of the mice he treated recovered all neurological function and achieved normal life expectancy.
While promising, this approach presents limitations for MS patients who would likely need repeated transplants. The treatment makes more sense initially for children born without myelin due to a rare genetic disorder, Dr. Goldman says.
"Stem-cell transplant in MS has been historically attractive, but has been overtaken by our understanding of how remyelination works and the potential of the brain's own stem cells," says Robin Franklin, who heads a neural stem cell program at the University of Cambridge in England.
According to Howard Weiner, who directs the Partners Multiple Sclerosis Center at Boston's Brigham and Women's Hospital, there are more leads right now aimed at shutting down the early part of the disease than on repairing damage.
"My own personal view is that I think we're better attacking the pathologic processes that are causing it as opposed to rebuilding after it's happened," Dr. Weiner says.
Write to Thomas Gryta at thomas.gryta@dowjones.com and Jon Kamp at jon.kamp@dowjones.com
good healthcare items here.
CeoCast Newsletter Sunday, January 17 2010
Companies featured in the current edition of the newsletter: CUR, DKAM, ENZ, FMTI, HYTM, IWEB, MFGD, NWCI, ONBI, PSID, SRCO
After sprinting out of the starting blocks to begin the year, stocks paused last week as disappointing earnings from Alcoa and JP Morgan, along with sluggish economic data helped temper, at least briefly, investors’ enthusiasm for equities. The Dow and S&p 500 each lost less than 1%, while the Nasdaq and the Russell 2000 bore the brunty of the selling pressure. The Dow lost 8 points, reducing its year-to-date gains to 1.7% after closing at 10609. The Nasdaq declined 29 points, or 1.3% t o 2287, but is still up 0.8% for the year. The S&P 500 fell nearly 9 points, but is up 1.9% for the year after closing at 1136. The Russell lost 6 points, but is still the best performing index, up 2% year-to-date.
Earnings Season began on a sour note, as Alcoa missed on the bottom line, resulting in its stock losing 11%. While JP Morgan Chase beat its bottom-line, it missed on the top-line, raising concerns that revenue growth would remain tepid at financial institutions for a while. Even Intel, which beat expectations on both the top and bottom-lines could not generate enthusiasm from investors, as the stock declined the day after earnings.
With Earnings Season in full force next week, volatility could increase. Investors may consider watching a key support/resistance level on the S&P 500. The S&P has been range bound between 1130 and the 1150 area. However, the chart suggests that after six consecutive “up” days to begin the year, that stock are "overbought" technically. If stocks should retreat, watch the 1130 area which lines up with the current November/December uptrend \ and the 20-day exponential moving average (1130). If support at that level doesn’t hold, the area around the 1110/1115 area, which marked the top of the November/December range and the 50-day moving averages.
Despite a holiday-shortened week, as the market is closed Monday for Martin Luther King Day, the earnings calendar will be extremely busy, with many of the most influential companies issuing results. Tuesday morning, Citigroup (NYSE: C) is scheduled to report results, while IBM (NYSE: IBM) is expected to post results after the bell.
Wednesday morning, Bank of New York (NYSE: BK), Morgan Stanley and Wells Fargo (NYSE: WFC) posts results, along with several influential regional banks. After the close, eBay (NASDAQ: EBAY), Starbucks (NYSE: SBUX) and Xilinx (NASDAQ: XLNX) report. On Thursday morning, Charles Schwab (NASDAQ: SCHW), Goldman Sachs (NYSE: GS) and PNC Bank (NYSE: PNC) issue earnings reports. After the close, look for American Express (NYSE: AXP) and Google (NASDAQ: GOOG) to report. On Friday morning, General Electric (NYSE: GE) posts results.
While investors are expected to focus on the earnings calendar, the election for Edward M. Kennedy’s vacant Senate seat on Tuesday could have broad implications for the economy. A win by Massachusetts Democrat Martha Coakley would give President Obama the majority he needs to pass his health care bill in the Senate. However, if Republican State Senator Scott Brown were to prevail, in what is widely viewed as a proxy on the President’s healthcare, taxes and government spending policies, it could derail Obama’s health care agenda. As of publication, the race was viewed as too close to call in the heavily Democratic state.
While the corporate calendar is busy, the economic calendar is relatively quiet. Tuesday there will be large auctions of Treasury Bills as the government will sell $23 billion of three-month and $25 billion of 6-month bonds. On Wednesday, December Housing Starts and Building Permits will be announced, along with the Producer Price Index for December, which is again expected to show that inflation is tame. Thursday brings the announcement of Weekly Jobless Claims, Leading Indicators for December and the January Philadelphia Fed Report.
Volume Alert: In one of the most astonishing volume breakouts we have seen in some time, shares of NewCardio, Inc., (OTCBB: NWCI) a cardiac diagnostic technology provider, nearly doubled last week on explosive volume, after an Internet blog suggested that the company could become an acquisition candidate. The stock, which was thinly traded until approximately two weeks ago, surged on more than 40 times average volume, culminating on Friday with the stock rallying more than 20% on 2.2 million shares. Interest may have been heightened after the company said last week that it received notice of allowance for U.S. patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing," from the U.S. Patent and Trademark Office. This represents the core patent for CardioBip, a unique, hand-held device that provides a solution for ECG telemonitoring. Shares ended the week at $1.88, up 93 cents.
Volume Alert: Shares of stem cell company Neuralstem (NYSE AMEX: CUR) continued to surge on heavy volume, jumping 23% last week on three times average trade, likely helped by the announcement last month that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells was approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA. The trial, which was approved by the FDA in September, will take place at the Emory ALS Center, under the direction of Dr. Jonathan Glass M.D., Director of the Emory ALS Center, who will serve as the site Principal Investigator. Shares ended the week at $2.40, up 45 cents.
Enzo Biochem, Inc. (NYSE: ENZ) said last week that its Clinical Labs division has become one of the first diagnostic laboratories to make available a rapid and sensitive H1N1 PCR test for the swine flu virus. Enzo Clinical Labs serves physicians throughout the Metropolitan New York area, as well as New Jersey and parts of Pennsylvania. The H1N1 identification is very specific, without cross-detection of other influenza variant subtypes according to the company. Shares ended the week at $5.89, down 25 cents.
Healthcare services company Hythiam (NASDAQ: HYTM) announced last week the publication of a paper titled, “Application of Multivariate Probabilistic (Bayesian) Networks to Substance use Disorder Risk Stratification and Cost Estimation,” in Perspectives in Health Information Management, Volume 6, Fall 2009. The predictive modeling work that forms the basis for the publication was sponsored by Hythiam to develop advanced tools for use in its Catasys program. The paper features the creation of predictive models that draw on historic healthcare claims and diagnostic data to estimate the expected future costs of a population with a substance dependence diagnosis, and that can stratify the population based on the expected benefit of intervention. Hythiam expects the models to be used to develop new and innovative approaches for substance dependence solutions that result in improved member care and reduced costs for healthcare payors. Shares ended the week at $0.52, down 2 cents.
PositiveID Corporation (NASDAQ: PSID) said last week that it plans to expand its HealthID division by adding products and tools for the daily management of diabetes. In addition to the continued development of its in vivo glucose-sensing RFID microchip to detect glucose levels in the human body, PSID is planning to broaden its technology platform by adding complementary non-invasive glucose-level testing technologies. According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion. Shares ended the week at $1.07, down 6 cents.
CEL-SCI Corporation (NYSE AMEX: CVM), a late-stage cancer company, reported results last week for the fiscal year ended September 30, 2009. CEL-SCI ended the year in its strongest financial condition ever, with more than $33 million in cash and cash equivalents and an unqualified audit report. A majority of the proceeds will be used for the company's upcoming Phase III clinical trial of its cancer drug Multikine. In connection with that, the company appointed Todd S. Burkhart as Vice President of Manufacturing/Facilities and Commercial Operations for its manufacturing facility. The company has a facility where it will produce Multikine. Shares ended the week at $0.94, up 4 cents.
Volume Alert: Shares of Money4Gold, Inc. (OTCBB: MFGD), an emerging global leader in direct-from-consumer, reverse logistics specializing in the procurement of precious metals and stones, surged nearly 16% on more than four times average volume last week. MFGD reported strong third quarter results for the period ended September 30, 2009, as the company reported gross revenue of $6.8 million, an increase of 871.4% compared to gross revenue of $0.7 million in the year-earlier period and 460.4% compared to gross revenue of $1.5 million in the previous quarter. The company said it expected “dramatic” revenue growth in the fourth quarter as well. The stock ended the week at $0.37, up 5 cents.
Forbes Medi-Tech (NASDAQ: FMTI) said last week that it has appealed its delisting to the Nasdaq Staff Deficiency Hearings Panel. The Nasdaq Staff Deficiency determination indicated that the Company does not meet The Nasdaq Capital Market initial listing standard as set forth in Listing Rule 5505. The Company will be preparing a plan to regain compliance with the NASDAQ initial listing standard and will be submitting the plan to the Panel. Shares ended the week at $0.30, down 1 cent.
IceWEB, Inc. (OTCBB: IWEB), a provider of cloud computing storage solutions, said last week that its Iplicity Data Storage platform fully enables disk storage capability available in non-Iplicity based legacy storage vendor products such as those produced by EMC Corporation, Network Appliance, Hitachi, Equalogic, Hewlett Packard, and IBM. Shares ended the week at $0.12, down 1 cent.
Drinks Americas Holdings, Ltd. (OTCBB: DKAM), an owner, developer and marketer of premium beverages associated with renowned icons, announced today that the company is planning to register an up to $30 million Rights Offering for tradable transferable subscription rights to purchase Units worth up to $30,000,000. Each holder of DKAM’s outstanding shares of Common Stock as of the Rights Offering record date will receive a dividend of one Right for each five hundred shares of Common Stock owned. Each Right shall be exercisable into one Unit, to consist of one voting share of Preferred Stock one three-year cash exercise Warrant exercisable into one share of Preferred Stock. Rightholders may also exchange their respective shares of Common Stock in lieu of cash for up to 50% of the amount of Rights that such investor is exercising at a ratio of five thousand shares of Common Stock for each one Unit. Shares ended the week at $0.029, unchanged.
Sparta Commercial Services, Inc. (OTCBB: SRCO) said last week that in the month of December the cities of Clovis, NM, Flagler Beach, FL, and Cocoa Beach, FL were the latest cities to join the local governments utilizing Sparta's Municipal Lease Program. Additionally, the city of Caldwell, TX has recently renewed its municipal leases for a second term. The Sparta Municipal Lease Program offers an alternative to the traditional outright purchases of equipment required by local, city, or state governments, enabling the agencies to lease their equipment, rather than purchase it, and thereby extend the payments over a period of several years. Sparta's Municipal Lease Program can support many other asset classes in addition to the police motorcycles leased by these cities. Shares ended the week at $0.035, up $0.005 cents.
On the Wires: One Bio Corp. (OTCBB: ONBI) announced today that it has bolstered its Board through the appointment of four independent directors: Professor Qingsheng Fan, James Fernandes, Jan Koe and Frank Klees. The executives have extensive experience in the pharmaceutical industry and strong financial credentials. In order to get listed on a national exchange, a majority of a company’s directors must be independent.
A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. This publication accepts compensation from companies that it features. This newsletter should not be regarded as an independent publication. Our editors may, from time to time, acquire positions in the companies that they cover. This could represent a conflict of interest. The CEOcast newsletter shall be under no obligation to inform readers about its trading activities. CEOcast's editors reserve the right to buy or sell shares in these companies at any time. The following companies, featured in this newsletter, have compensated CEOcast: Neuralstem seven-thousand five hundred dollars per month and forty-five thousand shares of stock for a six-month agreement. iceWEB, seven thousand five hundred dollars per month in cash, plus seven thousand five hundred dollars in stock per month for a six-month agreement, NewCardio, seven thousand five hundred dollars per month and two hundred thousand shares of stock for a six-month agreement, Forbes Medi-Tech, ten thousand dollars per month, Hythiam, ten thousand dollars per month and two hundred fifty thousand shares of stock for a one-year agreement, Drinks America, seven thousand five hundred dollars per month and six hundred thousand shares of stock, ONE Holdings, fourteen thousand three hundred seventy five dollars per month, CEL SCI Corporation, five thousand dollars and three hundred fifty thousand shares of stock for a one-year program, Money4Gold, nine thousand dollars per month and four hundred thousand shares of stock for a six-month agreement, Forbes Medi-Tech, twelve thousand five hundred dollars per month, Sparta Commercial, twelve thousand five hundred dollars per month through a combination of cash and stock, PositiveID, twelve thousand five hundred dollars per month for a one-year agreement.
--------------------------------------------------------------------------------
UNSUBSCRIBE
CBAI? looking good fer next week?
Human fetal Stem Cells http://www.medra.com/?gclid=COintdbHq58CFdx05QodUhRg0g
The Myeloma Program at Huntsman Cancer Institute is known for its tandem
transplant protocol, a treatment approach offered at very few medical centers around the country. Research demonstrates that the median
survival rate with this treatment process is 10 years or more and that 80% of newly-diagnosed myeloma patients will achieve complete remission. No other treatment method for myeloma has proven to be as effective in studies.
Since not all health insurance companies will cover a tandem transplant, it is important for patients to check with their insurance company to find out if they have coverage. If not, we have other effective myeloma treatments available as well.
We have two physicians who have been researching and treating multiple myeloma for over two decades, and all of our patients are assigned to one of these two doctors. It is our promise that for every doctor's appointment, our patients will see their myeloma specialist and never a less experienced physician.
Every patient deserves to have the opportunity to have all questions and concerns about their myeloma addressed. That is why we give all new patients approximately two hours with their myeloma specialist for the initial visit and approximately one hour for all future clinic visits. It is this kind of personalized care that sets us apart.
In addition to providing the best possible medical treatment from our internationally recognized myeloma specialists, we are dedicated to helping patients and their families cope with the emotional, social, physical, and financial challenges they face.
Stem cell treatment working for Vlada
Christian Peregin
Vlada Kravchenko was paralysed when a light structure fell on her in Qawra in September 2008. Photo: Matthew Mirabelli
Stem cell treatment is already working "miraculously" for paralysed teenager Vlada Kravchenko, who is now able to use her hips and thighs to crawl after suffering a horrific injury in Qawra in 2008.
"I don't just hope, I certainly know that I will walk again," the 18-year-old former gymnast said, explaining how the treatment will help her regain feeling and strength all the way down to her toes.
"I've been unable to move my legs since the accident. This feels amazing."
The doctors at the Moscow Neuro Vita Clinic were impressed by her progress after just one visit and told her she had great potential because of her age and the fact that she began treatment only a year after she was paralysed by a lighting structure which fell on her in September 2008 at a party in Qawra.
"Some patients take 15 years to seek this treatment after their accident," she added, optimistic that she will form part of the 10 per cent success rate.
Her mother said the recovery process had been miraculous, adding that her daughter had to train herself to walk like a child, starting from crawling and working her way up.
"We're going to have to do it all over again, but we will manage," she said.
Vlada was quick to add that the treatment does not work by itself. "You cannot sit down, watch TV, and expect to heal. I have to do exercises every day. Unfortunately, in Malta we don't have the kind of rehabilitation centres you find abroad - so I have to make do with what we have."
Vlada's experimental stem cell treatment is expensive. Each visit will cost her around €20,000, so over a period of two years she is expecting to pay up to €150,000.
Since she began her fundraising campaign last year, she managed to raise €10,000. However, she doubled the amount by borrowing money which enabled her to spend a month in Moscow.
She is still fighting for compensation from the people responsible for the lighting structure, which Vlada needs to continue raising funds in creative ways. She is in the process of organising a charity concert, since she hopes to go back to Moscow in May.
Besides the medical fees, there are several risks involved when her bone marrow cells are extracted and placed into her damaged spinal cord to stimulate nerve reconstruction. Some scientists have argued the cells can become cancerous.
But the aspiring model said she was not concerned about the risks and her experience in Moscow was "excellent".
"I wasn't a blind sheep. I asked the doctors questions about everything so I was absolutely informed. The risks are very minimal compared with the results I'm getting. Besides, with every type of treatment there will always be risks, but I would do it anyway," she said.
Vlada has established contact with an American girl with a similar but more severe injury, who is already on her ninth session of the treatment.
When she looks at how far her friend has come, Vlada is filled with hope and determination because she knows that her recovery may be even faster.
To help her campaign visit www.helpvlada.com.
cperegin@timesofmalta.com
Stem Cell Technique Holds Promise For Meat Production
Posted on: Saturday, 16 January 2010, 15:05 EST
A technology that allows pig stem cells to be converted into strips of meat might one day offer a solution to world hunger and a green alternative to raising livestock, scientists say.
Researchers in the Netherlands have been growing pork in laboratory environments since 2006, and while they acknowledge they have not perfected the texture or even tasted the meat, they say the technique has broad implications for the world’s food supply.
"If we took the stem cells from one pig and multiplied it by a factor of a million, we would need one million fewer pigs to get the same amount of meat," biologist Mark Post with Maastricht University told the Associated Press.
The university is part of the In-vitro Meat Consortium, a network of publicly funded Dutch research institutions that is conducting the experiments.
Post said the meat’s texture resembles that of a scallop – firm, but a bit squishy due to its lower protein content.
Other researchers in the U.S., Japan and Scandinavia are also working on ways to make meat in the laboratory, but the Dutch project is the most advanced, said Jason Matheny with Johns Hopkins Bloomberg School of Public Health in Baltimore, who has studied meat alternatives.
The U.S.-based research was funded by NASA, which had hoped the work might ultimately allow astronauts to grow their own meat in space. However, the space agency abandoned the initiative after results produced disappointingly thin sheets of tissue, deciding instead that it would be better for astronauts to simply eat vegetarian.
To produce pork in the lab, Post and his team isolated stem cells from pigs' muscle cells, and added them to a nutrient-based stew that helped the cells replicate to the targeted number.
To date, the scientists have only been able to create strips of meat about half an inch long. Post estimates it would take about 30 days of cell replication in the lab to make a small pork chop.
But the technology offers promising potential. For instance, fish stem cells could be used to produce healthy omega 3 fatty acids, which could be combined with the lab-made pork instead of the typical artery-clogging fats found in livestock meat.
"You could possibly design a hamburger that prevents heart attacks instead of causing them," Matheny told the Associated Press..
Post said the meat they have made so far could be used in sausages or hamburgers.
The biggest challenge now is reproducing protein content. Conventional livestock meat consists of up to 99 percent protein, whereas the lab meat is roughly 80 percent protein. Post said the lower protein content means the lab-made meat would not likely taste like pork.
The researchers say the technology should apply to other meats as well, including chicken, beef and lamb.
But some experts caution that lab-made meats could pose potential health threats for humans.
"With any new technology, there could be subtle impacts that need to be monitored," Emma Hockridge with the Soil Association, Britain's leading organic organization, told the Associated Press
Hockridge said organic farming relies on crop and livestock rotation, and that removing animals could damage the ecosystem. And it might take some time to prove the new technology isn’t harmful to humans, she said.
Other experts are skeptical that lab-produced meat could ever match the taste of real meat.
"What meat tastes like depends not just on the genetics, but what you feed the animals at particular times," biochemist Peter Ellis with King's College London told the AP.
"Part of our enjoyment of eating meat depends on the very complicated muscle and fat structure...whether that can be replicated is still a question,” he said.
If the technology proves out, the lab-produced meat could be a big benefit for the environment, some experts say.
Hanna Tuomisto with Oxford University, who studies the environmental impact of food production, said using lab-produced meat could theoretically reduce greenhouse gas emissions by up to 95 percent.
"In theory, if all the meat was replaced by cultured meat, it would be huge for the environment," she told the AP.
"One animal could produce many thousands of kilograms of meat."
Another benefit is that since lab meat can be “raised” with fairly few nutrients like amino acids, fats and natural sugars, it would reduce the need for the large amount of crops needed to nurture conventional livestock.
Widespread adoption of the technology also holds the potential to increase the world's meat supply, which could help fight global hunger, Tuomisto said.
Post hasn’t determined the commercial production costs of the technique. However, given that it would require less land, water and energy he estimates it would be equivalent to or lower than that of conventionally produced meat.
One of the most significant obstacles will be ramping up production to meet soaring global demand. By 2050, meat consumption is expected to double from current levels as developing nations consume more meat, according to the Food and Agriculture Organization.
"To produce meat at an industrial scale, we will need very large bioreactors, like those used to make vaccines or pasteurized milk," said Matheny, who thought the lab-produced meat could be commercially available within the next few years.
Post estimates it could take a bit longer, or about a decade.
For now, processed meats like hamburgers or hot dogs are the only types of meat they are proposing to create with the technique.
"As long as it's cheap enough and has been proven to be scientifically valid, I can't see any reason people wouldn't eat it," Stig Omholt, a genetics expert at the University of Life Sciences in Norway, told the Associated Press.
"If you look at the sausages and other things people are willing to eat these days, this should not be a big problem."
---
Morning Booger ! Im not a coffee drinker but was raised in a Household with a Very Strong work Ethics.Early to rise and late to fall!
Up and at em' early on a Saturday mornin'.............
Morning Locks....have another coffee
Stem Cell Utility Limited by Lack of Ethnic Diversity
Researchers stress the need to derive new lines that represent populations missing from currently available hESC
Patricia F. Dimond, Ph.D.
On December 2, 2009, NIH director, Francis S. Collins, M.D., Ph.D., announced the approval of the first 13 human embryonic stem cell (hESC) lines for NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted last July. And 12 days later, he sanctioned another 27 hESC lines. In accordance with the NIH guidelines, these stem cell lines were derived from embryos that were donated under ethically sound, informed-consent processes.
While investigators breathed a sigh of relief, scientists from Scripps Research Institute and separately from the University of Michigan reported a significant lack of ethnic diversity among available hESC lines. This will pose various problems as this technology becomes more widely used in research and clinical settings.
Cytochrome P-450 2D6 (CYP2D6) provides a significant example of ethnic variations at the genetic level. This enzyme is involved in the metabolism of close to 50% of all currently marketed drugs. Genotypic and phenotypic variations of the enzyme, however, often lead to major differences in the concentration of various drugs in the blood and the brain. As a result considerable differences in therapeutic responses and adverse drug effects are observed.
Analysis Points to Under-Represented Groups
The University of Michigan and Scripps groups used SNP analysis to study hESC lines to determine their ethnic origins, linking them to genetic signatures that could affect medical outcomes. Jeanne Loring, Ph.D., senior author of the Scripps paper published in Nature Methods and director of the Center for Regenerative Medicine at The Scripps Research Institute, and colleagues used data from the International HapMap Project.
The HapMap catalogs SNPs from 269 individuals for several million well-defined polymorphisms. It includes data from populations of four regions: Ibadan, Nigeria; Northern and Western Europe; 44 individuals from Tokyo; and 45 individuals from Beijing.
The Scripps team's analysis focused on 47 hESC lines and five widely used induced pluripotent stem cell (iPSC) lines. They demonstrated that these cells originated largely from Caucasian and East Asian populations, with little representation from populations originating in Africa.
The University of Michigan team used published data from 2,001 individuals of known ancestry whose genotypes were included in the HapMap and Human Genome Diversity projects. Their data included more than 480,000 SNPs in the human genome and also represented 47 hESC lines that had been developed in the U.S., Europe, Israel, and Singapore. More than half were cultured at Harvard University.
Their findings, reported in the New England Journal of Medicine, suggest that most hESC lines are of Northern and Western European ancestry. The Michigan group concluded that “efforts to derive and disseminate new stem cell lines should now emphasize under-represented populations to allow researchers to assess the extent to which the ancestry of stem cell lines influences disease models, cellular therapies, and drug screening. Availability of more diverse lines will reduce the risk that the potential benefits of stem cell research will be limited to patients with certain ancestries.”
For example, in 2008, scientists at the African Institute of Biomedical Science and Technology, Harare, Zimbabwe, and the University of Nairobi in Kenya suggested that the ineffectiveness of Bristol-Myers Squibb’s HIV drug Sustiva in the African population was linked to a gene variation seen more often among these people. They established a biobank and pharmacogenetics database of African populations and found a high frequency of individuals were homozygous for the CYP2B6*6 allele (18–25%). In Caucasians, on the other hand, CYP2B6*6 frequencies of 5–10% are more typical.
This is consistent with clinical observations that Africans have significantly higher plasma concentrations of Sustiva, a non-nucleoside reverse transcriptase inhibitor used as part of a highly active antiretroviral therapy compared to Caucasians when given at the standard 600 mg per day doses. The scientists thus indicate the need to lower the dose of this drug in people of African origin homozygous for the CYP2B6*6 allele. They believe that this could increase patient compliance and reduce costs.
Drug Development Leveraging hESC Lines
“Lack of genetic diversity among the currently available hESC lines will absolutely limit the value of hESC cells to the pharmaceutical industry,” Dr. Loring told GEN. Yet pharma companies have made and continue to make investments in hESCs for drug discovery, screening, development, and drug-toxicity assessments.
Last June GE Healthcare and Geron formed an alliance to develop and commercialize cellular assay products derived from hESCs that could be used in early in vitro screening of drug candidates to predict toxicity and pharmacological characteristics. The companies said that, for example, derivation of functional cell types from hESCs, in particular hepatocytes of the liver and cardiomyocytes of the heart, could provide a reliable supply of cells to perform metabolism, biodistribution, and toxicity testing of drug candidates.
The program will use hESC lines listed on the NIH Human Pluripotent Stem Cell Registry. The agreement grants GE Healthcare an exclusive license under Geron's extensive intellectual property portfolio covering the growth and differentiation of hESCs. It also gained a sublicense under Geron's rights to the hESC patents held by the Wisconsin Alumni Research Foundation.
Cellartis, a provider of stem cell derived products and technologies, and AstraZeneca initiated an alliance in 2006 to develop assays for target and lead validation, compound screening, drug metabolism studies, and safety assessment. The companies hope the hESC-derived cells will help researchers predict the human body's response to drugs more effectively than immortalized human cell lines, animal-derived cell lines, and tissues that are currently used by most drug makers, said Aileen Allsop, vp of R&D science policy for AstraZeneca.
Allsop pointed out that the firms began the collaboration as a very speculative, small-scale agreement, but AstraZeneca decided to extend the arrangement because it was beginning to give us some promising data. Jan Lundberg, who until November was AstraZeneca’s head of drug discovery, noted “Such a breakthrough could improve research and development productivity by reducing attrition rates and ultimately lead to safer medicines for patients.”
The iPSC Option
Scripps’ Dr. Loring thinks that availability of ethnically representative cell banks will require production of iPSCs, starting with normal fibroblast cell lines or similar. Her group at Scripps has begun to respond to the lack of diversity in hESCs by using skin cells from an individual of West African Yoruba heritage to create a new stem cell line. They claim that it is the first to carry the genetic profile of this ethnic group, expressing distinct genetic markers for disease risk and drug metabolism.
Dr. Loring’s group is working to differentiate the stem cells into cell types useful for drug discovery, screening, and toxicology. She cites the failure of Sustiva to completely address a population in critical need of an HIV drug as a stark example of requiring cells representative of distinct populations. She believes the derivation of iPSCs using cells from distinct populations will create more relevant models of drug development. Dr. Loring describes this work as the foundation of a new database of human pluripotent stem cell genetic information that will be available for other researchers to access for studies on specific genes, stem cell transplantation, and other topics.
iPSCs, however, come with their own set of drawbacks in terms of assessing and maintaining pluripotency. Indeed, hESCs as well require much research and investigation to become a viable source of therapies and a robust technology for drug development. Obtaining greater diversity is a good starting point to ensure that its potential is fully realized in all aspects of healthcare.
???
Patricia F. Dimond, Ph.D., is a principal at BioInsight Consulting. Email: drpdimond@comcast.net.
Dew....I've actually got a mini itx board mounted in the arm of the recliner powered by an intel E8600 dual core...mounted the power supply and hard drive under the chair in the interest of heat. I lift the arm of the chair up to access the on/off switch and/or usb ports or dvd drive. I use a usb wired lighted keyboard and wireless mouse. Works like a champ. I also built a monitor stand that allows me to position the 22" lcd anywhere I want (within reason). Yeah, it's a rough life lol....
Looking forward to next week.
hmmmm, now where's that little girl with the margarita’s
Booger, you're just like me. Got my laptop on my lap or close by, sitting in my easy chair all day, and watching TV. How come your L2 screen is bigger than your TV screen? LOL. I need to upgrade in both areas and will soon.
Nope !Its All good,Nite All
Yeah, I can see those things impacting my face.....OK, delete this post. lol
Science News Stem Cell Maintenance, Differentiation
ScienceDaily (Jan. 15, 2010) — While much of the promise of stem cells springs from their ability to develop into any cell type in the body, the biological workings that control that maturation process are still largely unknown.
--------------------------------------------------------------------------------
Writing in the online edition of the Proceedings of the National Academy of Sciences the week of Jan. 11, scientists from the University of Wisconsin-Madison and the University of California-Irvine present a new model of stem cell regulation.
Working with the small roundworm Caenorhabditis elegans, the researchers describe how a network of regulatory factors can maintain a stable pool of stem cells while launching a second pool of cells on the path toward maturing into differentiated cells with specific functions.
"This gives us a different way to think about how stem cells are controlled to leave their stem cell state and enter into a differentiated state," says Judith Kimble, a Howard Hughes Medical Institute investigator and UW-Madison professor of biochemistry who led the study.
"I think the basic principle is one that is very broadly applicable. The regulatory network is geared to define two states -- the stem cell state and the differentiated state -- and it's the regulation of that network that's important," Kimble says. "My guess is that this will also be true in other stem cell systems."
Regulation of the transition from stem cell to mature cell is important for a number of reasons, she says. Disruption of the balance between the two states could lead to tumors or loss of the ability to maintain healthy tissues.
Using the relatively simple worm allows them to study how stem cell populations respond to various physiological parameters in a whole animal and should help guide efforts to harness their blank-slate properties and to understand human diseases.
"Looking in vivo at how a stem cell is controlled to go from one state to another is really important if you want to intervene or engineer. This provides us a new way of thinking about it," Kimble says.
The new model also describes how a previously identified intermediate population of cells, possessing some properties of each state, probably reflects a gradual maturation process.
The specific factors that trigger cells to leave the stem cell state and begin to differentiate are still unknown, the scientists say, but the network of known regulatory factors already well understood in the worm provides several possibilities.
"Many of the same molecules control stem cells and development in humans and are involved in aberrant conditions," like leukemia and other cancers, Kimble says. "We hope to establish a procedure for understanding them in more complex systems."
In addition to Kimble, the paper was authored by Sarah Crittenden, Olivier Cinquin, and Dyan Morgan. Additional funding was provided by the National Institutes of Health.
Email or share this story:| More
All of the Potential Impact for sure!
Sorta comes out at you!LOL
The potential impact is amazing.
Page 5 is my favorite......
Your like the Energizer Bunny ..... just keeps on going and going...... lol. Good work though.
I'm in front of my pc all the time too, but you can see where I'm at.....in my recliner....in the den...
Michigan’s Aastrom Biosciences prices stock offering, shares tumble to 52-week low
January 15, 2010 by Brandon Glenn
Leave a Comment
Ann Arbor, Michigan — Biotech company Aastrom Biosciences Inc. announced the pricing of a 46-million-share public offering, sending its stock price tumbling to a 52-week low.
Aastrom, which is developing therapies that use stem cells to treat a number of chronic cardiovascular diseases, priced its shares at 26 cents per unit and hopes to raise $10.9 million from the offering. The pricing announcement sent the company’s shares plummeting as low as 22 cents Friday morning, before they rebounded slightly. Aastrom’s stock closed Thursday at 34 cents.
Aastrom said it plans to use the offering’s proceeds to fund operations and further clinical development of its stem-cell therapies.
The offering was underwritten by Oppenheimer & Co. and is expected to close Jan. 21, according to a statement from the company.
Aastrom is developing products that use a patient’s own stem cells to treat a variety of conditions, including arterial disease and chronic heart failure. The company went public in 1997.
It’s been a bumpy ride recently for Aastrom. In December, the company was granted an extension until March 31 from being delisted from the Nasdaq stock exchange. The company’s stock must trade above $1 for 10 consecutive days before that date, or it will be delisted. In its most recent financial disclosure, the company reported a loss of $3.9 million on revenue of $27,000 for the quarter ended Sept. 30.
In May, Aastrom halted a Phase 2 cardiac regeneration trial when a patient died after being released from the hospital following the trial. The trial, for patients with severe chronic heart failure, has been restarted. The company also is currently conducting a Phase 2b vascular regeneration clinical trial in patients with severe peripheral arterial disease.
Tim Mayleben, who has served on the company’s board since 2005, began his tenure as Aastrom’s new chief executive in December. Aastrom’s previous CEO, George Dunbar, earlier this month joined Ann Arbor venture-capital firm Arboretum Ventures.
Restoring Function after Stroke with Adult Stem Cells
by David Prentice
January 15, 2010
A new study indicates that function can be restored long after stroke damage by stimulating adult stem cells in the brain. Scientists at UC-Irvine found that a natural growth factor called Transforming Growth Factor-alpha (TGFa) stimulates adult stem cells in the affected brain to divide, migrate through the brain, and repair the damage. Using a rat model for stroke, they injected the TGFa protein directly into the brain as much as 4 weeks after the stroke damage, and found 99% recovery. Darius Gleason, a graduate student who worked on the study, said:
“It’s becoming more and more clear that the brain is like any other organ: It has a lot of potential to regenerate. We are just emulating nature by giving a little nudge to what the brain is trying to do itself.”
In a new study just published, the group has shown that even nasal administration of TGFa can give significant recovery (70%). This non-invasive route could have great therapeutic application. Previously, German researchers showed nasal administration of adult stem cells was an effective delivery method. This new study shows that using only the stimulatory protein can also be very effective at stimulating the existing adult stem cells already present in the brain.
A clinical trial is currently under way in Houston that injects the stroke patient’s bone marrow adult stem cells into the circulatory system; the cells seem to migrate to the injured brain and stimulate repair. Early results from this trial are very promising for stroke treatment
Running across the border for vital medical treatment
MY OPINION: Stem cell therapy
By Lionel Waxman, Inside Tucson Business
Published on Friday, January 15, 2010
There are at least three distinct stem cell therapies for degenerative and other diseases but the regulation of them is confusing to say the least. It is this confusion that has suppressed the availability of the therapies in the United States.
Fundamentally, the three kinds of therapies being used in the world today all involve the implantation of stem cells in the patient:
• The autologous transplant uses the patient’s own cells, usually extracted from the marrows of the hip. Rejection is avoided since they are the patient’s own cells. Print this storyEmail this storyPost a CommentShareThis
ADVERTISEMENT
• Synergeneic transplants where the donor cells are taken from an identical twin.
• Allogenic transplants in which the cells are taken from a more distant relative or from a total stranger.
It is that third kind that has caused considerable consternation because they are often taken from embryonic donors to which there are strong ethical objections. But there is also a procedure that uses cells taken from umbilical cord blood or placentas, the latter of which are otherwise useless and which do not raise ethical objections.
Yet the availability of all three kinds of transplants is avoided by clinics in the U.S.
Stem cell therapy has suffered a bad image because of the use of embryonic sources. But there is rarely a medical necessity to use embryonic cells when the most suitable donor would usually be the patient himself.
These cells have a most remarkable talent. They can circulate through the body and, finding tissue that needs repair, repair it. Obviously, it would be wasteful to use stem cells for so general a purpose, although some might. More typically, the cells are harvested from the patient, bred in order to multiply their numbers, concentrated, and then injected back into the patient’s body near the site needing repair or into a blood vessel that will carry them there.
These remarkable cells, find a problem and fix it. The therapy is almost miraculous. Would that they could run for political office.
Typically, the effect of the repair can be felt within a few hours. For patients with Multiple Sclerosis, Parkinson’s, stroke damage and a long list of others, this can represent a new lease on life.
And while that is true, patients with these disorders are usually told therapy is not available or they are sent to other countries to obtain it. Some of the major clinics doing this kind of work are in Germany, China and Mexico.
Stem cell implants are not covered by most insurance so the patient has to raise his or her own money for the procedure. The cost can range from $10,000 to more than $40,000 plus travel expenses. That is for each treatment, of which several may be required over time.
In my research for this column, I scoured the Internet, spoke to government agencies, researchers in the field, and patient support agencies. The confusion was remarkable. I received four kinds of responses to my inquiries: it’s illegal, it’s perfectly legal, we don’t really know, and most often, “You‘ll have to speak to (fill in blank). Hang on, I’ll switch you.”
Considering the toll, medical, social and economic these disorders take it is important that the law on the use of stem cells be clarified. If there were certainty that only embryonic stem cells were proscribed — which are the only ones to which there are ethical objection — there would be clinics all over this country, as there are in many others, offering this kind of treatment. That much competition would drive prices down and reduce or eliminate travel expenses.
We don’t know how to prevent these terrible disorders but if these treatments can get the sufferers out of their wheelchairs, out of their nursing homes and back to work, they will pay for themselves many times over economically and in the relief of innocent suffering.
Scientists use stem cells to produce pork in a laboratory
January 15, 2010 13:57 EST
LONDON (AP) -- Dutch scientists say they haven't got the texture right yet, but they have managed to grow pork in a lab using stem cells from pig muscles.
So far, they've only been able to grow meat strips half an inch long, but one of the researchers estimates a small pork chop would take about 30 days in the lab. Mark Post says the main problem is producing pork with the same protein content as regular meat. The lack of protein gives the petri pork a softer, flimsier consistency more like scallops.
Still, Post says the development could eventually offer an alternative to raising livestock and help ease hunger around the world.
One American researcher not involved in the Dutch study says the findings could also help develop healthier foods. For instance, healthy omega 3 fatty acids from fish stem cells could be mixed in to produce meat without the usual artery-clogging fats that come from livestock.
Other experts warn that lab-produced meat could pose health dangers.
None of the researchers have actually eaten the lab-made meat yet, but they're guessing it won't really taste like pork.
I plan on heading down to San Diego after the tour. I'm relaxing this weekend. ;)
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
Have fun and have a great weekend.
Happy days to you Med.rare... not sure what time zone you are in. ;)
Only those who will risk going too far can possibly find out how far one can go.
- T. S. Elliot
Dew... I go to a stem cell open house tomorrow and will be in Vegas too. ;)
Look forward to meeting you guys.
Only those who will risk going too far can possibly find out how far one can go.
- T. S. Elliot
This board is primarily for companies into cord blood storage since control of inventory will control treatments in the future. Discussion of updates in the field of stem cells and regenerative medicine will also be found.
Stem Cells – An overview
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/8/mUcE1Y_bOQE
Regenerative Medicine: Re-Growing Body Parts
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/16/GwcT1ViM-hw
Regenerative Medicine: Pathways to Cure - Version 2.0
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/15/tQ41GrOIbkE
The Stem Cell Stock Index
http://www.stemdex.com/2009/07/stem-cell-stock-index.html
The Stem Cell Tracker
http://www.stemcelltracker.com/
Diseases NOW Being Treated by Repair Stem Cells
http://repairstemcells.org/Treatment/Diseases-Treated.aspx
Global Cord Blood Stem Cells Market to Hit US$15 billion by 2015
http://www.prlog.org/10453315-global-cord-blood-stem-cells-market-to-hit-us15-billion-by-2015.html
Following are just a few of the companies in this arena. Listings are in alphabetical order by ticker:
ACTC - http://investorshub.advfn.com/boards/board.aspx?board_id=5319
http://www.advancedcell.com/
--------------------
AMST, formerly SCII - http://investorshub.advfn.com/boards/board.aspx?board_id=120
http://amsteminc.com/
--------------------
BCLI – http://investorshub.advfn.com/boards/board.aspx?board_id=4829
http://www.brainstorm-cell.com/
--------------------
CBAI - http://investorshub.advfn.com/boards/board.aspx?board_id=3650
Websites:
http://www.cordblood-america.com
http://www.cordpartners.com
http://www.cord-blood-video.com
http://www.curesource.net
http://www.corcell.com
--------------------
CCEL - http://investorshub.advfn.com/boards/board.aspx?board_id=3965
http://www.cryo-cell.com
Cryo-Cell Mexico offers services in Mexico, Central America and Ecuador.
Asia Cryo-Cell Private Limited offers services in India.
C'elle distributor opportunity for doctors that specialize in female issues. See video:
http://www.celle.com/distributorVideo.aspx#
--------------------
CO - http://investorshub.advfn.com/boards/board.aspx?board_id=16014
http://www.chinacordbloodcorp.com
--------------------
ISCO - http://investorshub.advfn.com/boards/board.aspx?board_id=13281
http://www.internationalstemcell.com/index.html
--------------------
SSS.V - http://investorshub.advfn.com/boards/board.aspx?board_id=11538
--------------------
Last update 4.20.2010
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board
Respect each other
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |